Global Search | Novartis

Hide Filters

Showing 2715 results

Ad hoc release / Nov 24, 2025

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III…
Ad hoc release / Nov 20, 2025

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for…
Big numbers
Immunology
Report side effects
test
Media Library / Nov 12, 2025

ME
Event / Nov 12, 2025

test Event
Tab content validation with existing implemetation
Tab content validation with existing implemetation